Literature Spotlight: Using Cogstate Digital Assessments to Identify Cognitive Impairment in Alzheimer’s Disease Clinical Trials

Cogstate digital cognitive assessments have been used extensively as rapid and reliable screening assessments in a range of clinical indications, including Alzheimer’s Disease (AD), Mild Cognitive Impairment, and Dementia. The tests are well-validated assessment options for study teams looking for an efficient and effective way to identify cognitive impairment in all phases of AD clinical trials.

From among Cogstate’s tests, the Cogstate Brief Battery (CBB) and International Shopping List Test (ISLT) are commonly used to assess cognitive impairment and change related to AD.

Download the Literature Spotlight below to learn more.

Download Literature Spotlight

Back to Fact Sheets